3rd Quarter - Report

RIVENDELL GROUP LLP for GENENTECH

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); Issues concerning implementation of Patient Protection and Affordable Care Act; Drug pricing under 340B program; Cancer Patient Protection; Ongoing issues related to the implementation of the Affordable Care Act; Comparative effectiveness research, and FDA approval of follow-on biologics; Reimbursement and patient access issues associated with CMMI Medicare Part B Drug Payment Model proposal and demo project; Vice President Cancer Moon Shot Initiative

LobbyistCovered position, as disclosed
MATTHEW LAWRENCE BERZOK LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch
NICK KOLOVOS LA and Counsel, Rep. Anna Eshoo

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Concerns regarding Medicare policies for Part B drugs; Issues related to the 340B Drug discount program; Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; Issues relating to Prescription Drug User Fee Act and ASP +6; Issues related to comparative effectiveness and follow-on biologics; Issues related to 340B; 21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); Issues concerning implementation of Patient Protection and Affordable Care Act; HR 1470 and S.810, the SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Medicare physician payment reform, payment for Part B drugs; Reimbursement and patient access issues associated with CMMI proposed Medicare Part B Drug Payment Model Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6 and Part B Demo; issues related to comparative effectiveness and follow-on biologics;

LobbyistCovered position, as disclosed
MATTHEW LAWRENCE BERZOK LD and Chief Counsel, Rep. Bart Stupak; LA, Rep. Peter Deutsch
NICK KOLOVOS LA and Counsel, Rep. Anna Eshoo

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1470 (114th), S. 810 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.